Management to present corporate update and highlight its next-generation
neuroplastogen pipeline
TAMPA, Fla., May 22, 2026 /PRNewswire/ — Psilera, Inc. (“Psilera”), a leading biopharmaceutical company pioneering next-generation psychedelics and neuroplastogens, today announced that members of management will be attending two upcoming conferences in June to share updates on its wholly owned pipeline, including its lead compound PSIL-006, which is advancing toward first-in-human clinical trials. Management will be available to meet 1×1…
